AlphAIalphai — Financial news for AI agents
newsday.comAUG 86 min read$MRNA

The new mRNA flu shot mFlusiva is more effective. Why doctors worry Long Islanders may not try it.

The FDA approved Moderna’s mFlusiva mRNA flu vaccine for people ages 50 and older, citing a study of 40,000+ participants ages 50 to 64 showing 26.6% higher effectiveness versus a traditional flu vaccine. Approval for ages 65+ is provisional pending more data. The article also discusses potential benefits and public concern about mRNA technology.

Original reporting
newsday.com
Published Aug 8, 2026, 2:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 9, 2026, 5:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
The new mRNA flu shot mFlusiva is more effective. Why doctors worry Long Islanders may not try it. — source image
Source · newsday.com
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The approval is a concrete regulatory milestone with quantified effectiveness versus traditional-dose flu vaccines, but the article emphasizes that misinformation about mRNA could suppress uptake and that 65+ approval is conditional pending further studies.

02

Market read

Traders get a fresh FDA approval with a specific effectiveness figure, plus a clear demand risk from mRNA skepticism and conditionality for the oldest cohort.

03

What to watch

Adoption depends on communication and clinician endorsement, and the conditional nature of 65+ approval could delay full market penetration.

Relevance 8/10Novelty 8/10Timing: FDA approval reported Wednesday, ahead of the coming flu season rollout in pharmacies.

Background

The FDA approved Moderna’s mRNA flu vaccine mFlusiva, the second FDA-approved mRNA vaccine after COVID, using messenger RNA to target circulating flu strains.

Company-level read

Ticker impact

$MRNABullishMedium confidence
Context

FDA approved Moderna’s mRNA flu vaccine mFlusiva for ages 50+ after a 40,000-person study showed 26.6% higher effectiveness.

Expected impact

Moderate positive bias for MRNA on approval narrative, with follow-through dependent on uptake and any additional 65+ data.

Evidence & confidence

The article discloses a fresh FDA approval and quantified effectiveness, but it also highlights adoption risk from misinformation and conditionality for older age groups.

Market effects

Sector

Supports the broader mRNA vaccine platform thesis for non-COVID indications, potentially improving sentiment toward next-gen vaccine developers.

Regional

Long Island pharmacy availability is mentioned, but the commercial impact is likely national rather than region-specific.

Global

If uptake improves, it reinforces a global shift toward faster, strain-matched vaccine manufacturing.

Counterpoint

What could challenge this read

The headline effectiveness advantage may not translate into revenue if public distrust keeps vaccination rates low and 65+ remains provisional.

Key entities

  • company
    Moderna

    Developer of mFlusiva, whose FDA approval and study results are the core new facts in the article.

  • regulator
    FDA

    Approved mFlusiva for ages 50+ and set conditional approval for ages 65+.

  • product
    mFlusiva

    Moderna’s mRNA flu vaccine, reported as 26.6% more effective in the cited study.

Read at source← All news

Related articles

AUG 9
$MRNAMedAI 9/10

FDA Approves New, More Effective Flu Vaccine From Moderna

The FDA approved Moderna’s mRNA flu vaccine, mFlusiva, for adults 50 to 64 and 65 and older, according to Moderna. The company said it is about 27% more effective than standard flu shots, citing roughly 83% effectiveness versus typical 22% to 56%. The article notes CDC data on U.S. flu deaths in 2025.

aol.com3 min
AUG 8
$MRNAMedAI 8/10

New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

The FDA approved Moderna’s mRNA-based flu vaccine mFlusiva for adults 50+. According to Moderna, full approval covers ages 50 to 64 based on a 40,000-person study showing 27% fewer flu cases versus a common comparator. For ages 65+, accelerated approval was granted based on immune response versus a high-dose vaccine. Moderna expects limited retail availability soon.

japantoday.com4 min
AUG 8
$MRNAMedAI 8/10

ever mRNA flu shot for older adults

The FDA granted full approval to Moderna’s mRNA flu vaccine, mFlusiva, using COVID-19 mRNA technology, for adults ages 50 to 64. The manufacturer says it is 27% more effective than existing flu vaccines. The article notes expected injection-site reactions and possible fever, and says it should be available soon.

aol.com3 min
AUG 8
$MRNAMedAI 8/10

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Moderna’s Q2 2026 earnings call covered pipeline updates and financial results. The company said it will add a Phase III cohort for norovirus vaccine mRNA-1403 after an interim analysis, and reported Q2 revenue of $145 million, net loss of $782 million, and cash and investments of $6.9 billion. Moderna reiterated 2026 revenue growth up to 10% and updated cost guidance.

yahoo.com6 min
AUG 7
$MRNAMedAI 8/10

FDA Approves First mRNA Flu Vaccine for Older Adults

The FDA approved Moderna’s mRNA flu vaccine mFLUSIVA for adults aged 50 to 64 at higher risk of infection. Moderna said Phase 3 testing of 40,805 participants across 11 countries showed 27% greater effectiveness than the standard shot and an acceptable safety profile. Moderna expects production in 2 to 3 months for the upcoming flu season.

legalinsurrection.com4 min
AUG 7
$MRNAMedAI 8/10

FDA Approves mFlusiva, First mRNA Flu Vaccine

The FDA approved Moderna’s mFlusiva, the first mRNA flu vaccine in the US. Adults 50 to 64 received full approval based on a trial of 40,000+ showing about 27% higher effectiveness versus a standard-dose flu vaccine. Adults 65+ received accelerated approval based on immune response versus a high-dose vaccine; Moderna says production can take 2 to 3 months.

everydayhealth.com4 min